Alkylphosphocholines and quaternary ammonium compounds against <i>Acanthamoeba keratitis</i> by Mooney, Ronnie & Williams, Roderick
 
UWS Academic Portal
Alkylphosphocholines and quaternary ammonium compounds against Acanthamoeba
keratitis
Mooney, Ronnie; Williams, Roderick
Published in:
Journal of Ophthalmological Science
Published: 31/07/2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication on the UWS Academic Portal
Citation for published version (APA):
Mooney, R., & Williams, R. (2020). Alkylphosphocholines and quaternary ammonium compounds against
Acanthamoeba keratitis. Journal of Ophthalmological Science, 2(2), 5-14.
https://ophthalmolscience.com/articles/alkylphosphocholines-and-quaternary-ammonium-compounds-against-
acanthamoeba-keratitis.html
General rights
Copyright and moral rights for the publications made accessible in the UWS Academic Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
Take down policy
If you believe that this document breaches copyright please contact pure@uws.ac.uk providing details, and we will remove access to the
work immediately and investigate your claim.
Download date: 30 Nov 2020
Mooney R, Williams R. Alkylphosphocholines and Quaternary Ammonium Compounds 
against Acanthamoeba Keratitis. J Ophthalmol Sci. 2020;2(2):5-14
Mini Review Article Open Access
Page 5 of 14
Alkylphosphocholines and Quaternary Ammonium Compounds against 
Acanthamoeba Keratitis
Ronnie Mooney*, Roderick Williams
Institute of Biomedical and Environmental Health Research, University of the West of Scotland, School of Health and Life Sciences, High Street, Paisley, PA1 2BE, 
Scotland, UK.
Article Info
Article Notes 
Received: July 01, 2020
Accepted: July 31, 2020
*Correspondence: 
Ronnie Mooney, Institute of Biomedical and Environmental Health 
Research, University of the West of Scotland, School of Health and 
Life Sciences, High Street, Paisley, PA1 2BE, Scotland, UK; Email: 
ronnie.mooney@uws.ac.uk.
©2020 Mooney R. This article is distributed under the terms of 
the Creative Commons Attribution 4.0 International License.
Keywords: 
Acanthamoeba
Keratitis
Alkylphosphocholines
Quaternary ammonium compounds
Miltefosine
Contact lens solution
Preservative
  
Abstract
Acanthamoeba keratitis (AK) is a sight threatening infection caused by 
the free-living amoeba Acanthamoeba. This infection is largely associated 
with contact lens wear and the recent increase in AK incidences highlights 
the ineffectiveness of existing curative and preventative treatments. Current 
curative and protective treatments being active in part, only against the 
infective trophozoites and often inducing their conversion to the protective 
cysts is a major issue, particularly when the latter are the main cause of disease 
resurgences and relapses. These point to the need for the discovery of new 
drugs for curative and preventive treatments. Two structurally similar chemical 
classes, alkylphosphocholines (APCs) and quaternary ammonium compounds 
(QACs) that address these issues will be discussed in this review. 
Introduction
Acanthamoeba are free-living single celled eukaryotes, existing 
in two forms; an infective trophozoite and a dormant cyst. They are 
ubiquitously found in both natural and man-made environments and 
are of clinical relevance due to their opportunistic parasitic activities 
in humans1. There are several Acanthamoeba associated infections 
in humans, but this review will focus on the sight threatening 
disease of the eye Acanthamoeba keratitis (AK)2 and the use of two 
promising compounds as curative and preventive treatments that 
will validate its incorporation into contact lens solutions. Curative 
treatment is the use of systemic oral drugs and topical eye drops 
while preventive treatment employs medical devices e.g. contact 
lens solutions to sterilise contaminated lenses and prevent contact 
lens to eye transmission. 
AK is largely associated with improper contact lens hygiene and 
the limited activity of contact lens solutions against Acanthamoeba. 
The attachment of Acanthamoeba to contact lens allows transmission 
to, and infection of the cornea arising from the feeding activities of 
trophozoites in the eye3. Incidence rates of AK have been increasing 
globally since the start of the 21st century. On average, the annual 
number of AK cases within the Moorfields eye hospital, England 
increased from 12.8 to 48.6 between 2000-2008 and 2009-20164, 
and 16 to 49 in the Netherlands between 2009 and 20155. Similar 
reports are documented in Australia and the USA with rising 
incidences, the Sydney Eye Hospital reported the annual average 
cases of AK to be 2.6 and 3.6 before and after 20076, while cases in 
Iowa, USA increased in average annual cases from 2.9 to 6.5 between 
2002-2009 and 2010-2017 respectively7. The reasons for this spatio-
temporal increase are not readily apparent but improved diagnostic 
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techniques and ineffective contact lens cleansing solutions 
are thought to be key factors4.
Existing curative and preventive treatments for 
AK mainly target trophozoites but become inactive if 
they induce their conversion to cysts via the process of 
encystation8. The cellulose cell walls of cysts protect the 
parasite against drug activity9,10 and the reduction of drug 
concentrations in the eye to sub-lethal levels initiates the 
reversion of cysts to the trophozoite stage, ultimately 
leading to disease resurgence10. 
The inability of current topical and oral drugs and 
many widely used contact lens solutions to produce death 
at low concentrations against cysts, the requirement of a 
prolonged treatment regime to ensure complete clearance 
from the eye and the ability to induce encystation are factors 
that have made AK treatment and prevention difficult11. In 
some instances, frequent application of drugs topically for 
up to a year is required, causing corneal damage and very 
often patients require surgical intervention e.g. corneal 
transplant to repair the damaged cornea10,12. Preventive 
protocols with commonly used contact lens solutions such 
as one-step hydrogen peroxide solutions are similarly 
ineffective with even compliant users at risk13,14. 
Two structurally similar compounds named 
alkylphosphocholines (APCs) and quaternary ammonium 
compounds (QACs) have received attention for their 
activity against several protozoan pathogens, including 
Acanthamoeba15–20. These compounds are active 
against cysts and synergistic with other antimicrobials 
including Acanthamoeba spp15-21. Work by Walochnik and 
colleagues on their anti-amoebic properties for combating 
Acanthamoeba keratitis concluded that APCs are promising 
drug candidates that might prove useful against AK21. This 
minireview provides an update and the state of the art of 
this chemical class and an analogue called QACs, extensively 
used as preventative strategy against AK. 
Alkylphosphocholines against Acanthamoeba 
Keratitis
Structure of alkylphosphocholines
APCs are zwitterionic molecules comprised of a head 
made from a trimethylamine moiety containing a positively 
charged nitrogen atom and joined by a two alkyl-carbon 
linker to a negatively charged phosphoryl group. The tail, 
made of varied number of alkyl-carbons, is attached to the 
phosphoryl group (Figure 1). 
Activity of oral miltefosine against Acanthamoeba 
keratitis
The APC, miltefosine was first developed as an anti-
cancer drug but was subsequently shown to have anti-
fungal and anti-protozoal properties20,22–27. Systemic use of 
miltefosine was licensed in the USA as a treatment of AK in 
2016 and when incorporated into treatment regimens at 
50mg/ml, given three times daily (TD) for up to two months 
has proved to be an effective oral systemic treatment 
against Acanthamoeba mainly in combination15,28 (Table 1). 
The use of miltefosine solely as an oral administration is yet 
to be tested, but in combination with topical applications 
e.g. chlorhexidine (0.06%) and propamidine (0.1%) has 
demonstrated success15. Hirabayashi et al.15 reported the 
use of miltefosine in the treatment of a patient suffering 
with progressively worsening AK. For this 17yr old female 
patient, earlier treatments with topical polyhexamethylene 
biguanide (PHMB, 0.02%), chlorhexidine (0.02%), 
moxifloxacin (0.5%), cyclopentolate (1%) and oral 
administration of both 500mg valacyclovir and 200mg 
voriconazole twice daily (BD) were unsuccessful. The 
addition of miltefosine (50mg, TD, orally) in particularly 
with topical chlorhexidine (0.06%) and propamidine 
isethionate (0.1%) for five weeks reduced the infection 
and accompanying symptoms, pain improved conjunctival 
injection and corneal opacity were reduced and improved 
respectively15. No resurgence was observed one-year post 
treatment15 (Table 1). Similar results have been described 
by Dewan et al28 , again a 44yr old female who did not 
respond to treatment with topical chlorhexidine (0.02%), 
PHMB (0.02%,), gatifloxacin (0.3%) and voriconazole 
(0.5mg/ml) and oral voriconazole (200mg, BD) was 
responsive to oral miltefosine (50mg, TD) after 11 months 
of treatment28 (Table 1). Resurgence was not evident 
thirty-month post treatment28. The efficacy of miltefosine is 
reproducible and has been replicated in part by Naranjo et 
Figure 1: General structure of an alkylphosphocholine. The molecule is comprised of a negatively charged phosphoryl group and positively 
charged nitrogen joined by a linker made from two alkyl-carbons which forms a neutrally charged head group. The tail is comprised of 
varied length of alkyl-carbon chain with different degree of unsaturation and can be with sulphur and oxygen substitutions for the 
hydrogen joined to the phosphoryl moiety. “n” indicates the variable alkyl-carbon tail.
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Participant 
specifics
Treatment regimen prior to miltefosine 
usage Treatment regimen with miltefosine Remarks Ref.
17-year old 
female
T1: Several Months - Antivirals and 
topical corticosteroids administered for 
several months. 
T2: 2 weeks – Topical; PHMB (0.02%; 
q1h)/Chlorhexidine (0.02%; QD), Moxi-
floxacin (0.5%; TD), cyclopentoate (1%; 
OD), Oral; valacyclovir (500mg; OD) 
T3: 6 weeks; - Oral; Valacyclovir dis-
continued and replaced voriconazole 
(200mg; BD) 
T4: 1 week – Topical; PHMB (0.02%; q1h)/
Chlorhexidine (0.02%; QD), Moxifloxacin 
(0.5%; QD), cyclopentoate (1%; TD), Oral; 
miltefosine (50mg; TD) 
T5: Undisclosed time – Topical; PHMB 
(0.02%; QD)/Chlorhexidine (0.02%), Oral; 
miltefosine (50mg; TD), doxycline (50mg; 
BD), OD Vitamin C (1000mg; OD) 
T6: 5 weeks - Topical; PHMB was discontin-
ued while treatment in T5 updated with 
Chlorhexidine (0.06%; q1h) and propami-
dine isethionate (0.1%; q2h) 
T7: Undisclosed time – Topical; Chlorhex-
idine (0.06%; q2h), Oral; BD Miltefosine 
(50mg; BD) 
T8: 2 months – Topical; Chlorhexidine 
(0.06%; QD)/propamidine isetionate 
(0.1%, QD), Oral; Miltefosine (50mg; OD) 
T9: 1 year - Miltefosine discontinued but 
treatment described in T8 continued for 
1 year
- Cultures were negative for Acan-
thamoeba after T9. 
- Pain, conjunctival injection and 
cornea opacity decreased signifi-
cantly after five weeks treatment 
with miltefosine (50mg; TD oral), 
chlorhexidine (0.06%; q1h topical), 
propamidine isethionate (0.1%; q2h 
topical), doxycline (50mg; BD oral) 
and Vitamin C (1000mg; OD oral) 
(See T6)
- No recurrence was observed one 
year post treatment with miltefos-
ine (see T9)
15
44-year old 
female
T1: 4 weeks (inconsistently) - Topi-
cal; prednisolone acetate (1%; q1h), 
dexamethasone sodium phosphate 
ointment (0.1%; OD), homatropine (2%; 
BD) 
T2: 2 weeks - Topical; tobramycin (0.3%; 
OD), dexamethasone ophthalmic 
ointment (0.1%; OD), gatifloxacin (0.3%; 
QD) 
T3: Undisclosed time - Topical; chlorhex-
idine (0.02%; q1h)/PHMB (0.02%;q1h), 
gatifloxacin (0.3%; QD)
T4: 3 weeks - Topical; prednisolone 
acetate (1%; QD), voriconazole (0.5mg.
ml; q1h) added, Oral; voriconazole 
(200mg; BD)
T5: 3 months - Topical; Voriconazole 
(0.5mg) discontinued, chlorhexidine 
(0.02%;q1h)/PHMB (0.02%;q1h), gatiflox-
acin (0.3%; QD), prednisolone acetate 
(1%; QD) Oral; Miltefosine (50mg; TD), 
Voriconazole (200mg; BD)
T6: 3 months - Topical; prednisolone 
acetate (1%; q2h), chlorhexidine (0.02%; 
q2h), PHMB (0.02%; q2h) Oral; Miltefosine 
(50mg; BD), Voriconazole (200mg; BD)
- Cultures were native for Acan-
thamoeba after T6
- Standard treatments for AK (T1 to 
T4) were unsuccessful, but the addi-
tion of miltefosine in T5 to T6 cleared 
the infection
- No disease resurgence observed 
30 months post treatment (T6)
28
29-year old 
female
T1: 2 days - Topical; ganciclovir gel (n/a), 
erythromycin ointment (n/a), Oral; 
valacyclovir (n/a)
T2: 5 days - Topical; empiric fortified 
vancomycin (n/a), tobramycin eye drops 
(n/a)
T3: 2 weeks - Topical; fortified vancomy-
cin discontinued, chlorhexidine (n/a), 
PHMB (n/a), polymyxin/trimethoprim 
(n/a) added
T4: 15 days - Topical; chlorhexidine (n/a), 
PHMB (n/a), polymyxin/trimethoprim 
(n/a) Oral; miltefosine (50mg; TD)
T5: 13 days - Topical; PHMB (n/a), pred-
nisolone acetate (1%) propamidine (n/a) 
Oral; see T4
- Cultures were negative for Acan-
thamoeba afrer T 5
- Patients symptoms worsened after 
6 days treatment with miltefosine, 
predicted to be immune related (T4)
- Cultures returned negative for 
Acanthamoeba, only one cyst was 
identified in histopathological 
analysis 
- No disease recurrence noted 12 
months post treatment (T5) 
29
53-year old 
female
T1: Undisclosed time - Topical; ganci-
clovir ophthalmic gel (0.15%), prednis-
olone acetate (1%), Oral; valacyclovir 
(n/a)
T2: Several months - Topical; chlorhexi-
dine (n/a), propamidine (n/a)
T3: 15 days - Topical; chlorhexidine (n/a), 
Oral; miltefosine (50mg; TD)
T4: 20 days - Topical; chlorhexidine (n/a), 
PHMB (n/a), Oral; see T3
- Cultures were negative for Acan-
thamoeba afrer T 4
- Symptoms worsened after 15 
days treatment with miltefosine, 
presumed immune related (T3)
- no disease recurrence noted 5 
months post treatment (T4)
29
Table 1: Oral miltefosine against Acanthamoeba keratitis
Mooney R, Williams R. Alkylphosphocholines and Quaternary Ammonium Compounds 
against Acanthamoeba Keratitis. J Ophthalmol Sci. 2020;2(2):5-14 Journal of Ophthalmological Science
Page 8 of 14
24-year old 
female
T1: 3 weeks - Topical; ganciclovir oph-
thalmic gel (0.15%)
T2: 2 weeks - Topical; ganciclovir oph-
thalmic gel (0.15%) prednisolone (n/a), 
Oral; valacyclovir (n/a)
T3: 20 days - Topical; PHMB (n/a; q1h) 
added, Oral; see T2
T4: 28 days - Topical; ganciclovir ophthal-
mic gel (0.15%), prednisolone, PHMB 
(n/a; q4h), Oral; Miltefosine (50mg; BD), 
valacyclovir (n/a)
- Cultures were negative for Acan-
thamoeba afrer T 4
- Symptoms worsened after 12 
days treatment with miltefosine, 
presumed immune related (T4)
- no disease recurrence noted 9 
months post treatment (T4)
29
25-year old 
female
T1: Several weeks - Topical; ganciclovir 
ophthalmic gel (n/a) ofloxacin drops 
(n/a), Oral; famcyclovir (n/a)
T2: 40 days - Topical; propamidine isethi-
onate (n/a), PHMB (n/a), polymyxin/tri-
methoprim (n/a) Oral; valacyclovir (n/a)
T3: 28 days - Topical; propamidine isethi-
onate (n/a), PHMB (n/a), polymyxin/tri-
methoprim (n/a) Oral; Miltefosine (50mg; 
TD), fluconazole (n/a)
- Cultures were negative for Acan-
thamoeba afrer T 3
- Symptoms improved after 8 days 
treatment with miltefosine (T3)
- no disease recurrence noted 9 
months post treatment (T3)
29
16-year old 
female
T1: Several weeks - Topical; predniso-
lone acetate (n/a), Oral; acyclovir (n/a)
T2: 1 month - Topical; PHMB (n/a), 
chlorhexidine (n/a), Oral; see T1
T3: 2 months - Topical; chlorhexidine 
discontinued, propamidine isethionate 
(n/a) added Oral; see T1
T4: 28 days - Topical; PHMB (n/a), propa-
midine isetionate (n/a), Oral; Miltefosine 
(50mg; BD), acyclovir (n/a)
- Cultures were negative for Acan-
thamoeba afrer T 4
- Symptoms improved after 20 days 
treatment with miltefosine (T4)
- no disease recurrence noted 9 
months post treatment (T4)
29
55-year old 
female 
T1: Undisclosed time - Topical; erythro-
mycin (n/a), besifloxacin (n/a), valacy-
clovir (n/a), and difluprednate (n/a)
T2: Undisclosed time – Topical; moxifloxa-
cin (n/a), bacitracin (n/a), polymyxin B (n/a)
T3: 6 weeks – Topical; moxifloxacin 
(n/a), bacitracin (n/a), polymyxin B (n/a) 
discontinued, PHMB (n/a), propamidine 
isethionate (n/a), cyclopentolate eye 
drops (n/a) added
T4: 28 days - Topical; PHMB (n/a), propa-
midine isethionate (n/a), cyclopentolate 
eye drops (n/a) Oral; Miltefosine (50mg; 
TD)
T5: 1 month - Topical; PHMB (n/a), steroids 
(n/a) Oral; Miltefosine (50mg) discontin-
ued
- Cultures were negative for Acan-
thamoeba afrer T 5
- Symptoms worsened after 21 
days treatment with miltefosine, 
presumed immune related (T4)
- no disease recurrence noted 8 
weeks post treatment (T5)
29
59-year old 
male
T1: 1 month - Topical; ofloxacin (n/a)
T2: 2 weeks - Topical; PHMB (0.02%; 
q1h), Oral; voriconazole (400mg; BD), 
reduced (200mg and eventually discon-
tinued within this time
T3: 1 week - Topical; PHMB (0.02%; 
q2h), dexamethasone (0.1%)
T4: Undisclosed time - Topical; PHMB 
(0.02%; q1h) 
T5: 2 weeks - Topical; PHMB (0.06%; 
q1h), hexamidine (0.1%; q1h), levoflox-
acin (0.5%; q1h)
T6: 4 weeks - Topical; hexamidine 
(0.1%), levofloxacin (0.5%) discontin-
ued, PHMB (0.06%; QD), prednisolone 
(0.5; QD) added
T7: 2 months - Topical; QD PHMB 
(0.02%), QD dexamethasone (0.1%)
T8: 2 months - Topical; q1h PHMB 
(0.02%), q1h chlorhexidine (0.02%), 
q1h hexamidine (0.1%), q1h cefuroxime 
(5%), q1h gentamicin (1.5%)
T9: Undisclosed time - Topical; q1h chlor-
hexidine (0.2%), q1h imidazole (1%), QD 
cefuroxime (5%), QD gentamicin (1.5%), 
QD predforte (1%) Oral; BD posacon-
azole (300mg), BD tacrolimus (1mg), 
Intravenous; methylprednisolone (1g), 
Intracameral; voriconazole (0.5μg/ml) 
T9: 2 weeks - Topical; chlorhexidine (0.2%; 
q1h), imidazole (1%; q1h), cefuroxime (5%; 
QD), gentamicin (1.5%; QD), predforte 
(1%; QD) Oral; tacrolimus (1mg) discontin-
ued, Miltefosine (50mg; TD), posaconazole 
(300mg; BD), 
- Cultures were negative for Acan-
thamoeba afrer T 9
- Miltefosine administered prior to 
surgery to prevent the spread of 
Acanthamoeba to the CNS (T9) 
- Amoeba were not cleared but no 
spread was documented (T9)
- Amoeba present in the vitreous 
but further spread to the retina, 
choroid and optic nerve was pre-
vented, not clear if this is a result of 
miltefosine treatment however (T9) 
32
Key: Tn – Treatment intervention sequence where n is number of intervention, OD - once daily, BD - twice daily, TD - three times daily, QD - four 
times daily, qxh - taken every x hours, where x is the duration.
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al.29. Oral miltefosine (50mg, TD) was effective and reduced 
parasite load in the eye of the patient after three weeks, 
with no re-infection noted29 (Table 1). However, in four 
out of six cases, inflammatory responses produced either 
by the eye immunity towards the killed Acanthamoeba or 
the immunomodulatory effect of miltefosine produced 
deterioration in the eye which was corrected by 
penetrating keratoplasty29. Studies of the combination 
of this compound with anti-inflammatory medication is 
required to determine if managing the immune response 
could improve treatment, although it has been suggested 
that miltefosine might be used as an immune modulating 
anti-inflammatory compound so an extensive investigation 
of this inflammatory effect would be required30. 
Miltefosine is yet to be licensed for AK treatment in 
UK, but clinical trials to prevent trophozoites migration 
from the eye to the central nervous system, resulting in 
granulomatous amoebic encephalitis (GAE), an infection 
with a mortality rate of 90%31, has proven successful32. 
Preliminary results based on histopathological analysis 
showed that while migration was halted, the infection 
was not cleared from the eye. However, treatment with 
miltefosine was only administered for two-weeks prior to 
surgery32. These results show that the treatment of AK is 
complicated and marred with issues of toxicity and dosage 
regime (Table 1) but confirms that miltefosine is a bona 
fide treatment for AK in combination with the standard 
topical treatments particularly when they are ineffective.
Activity of topical miltefosine against Acanthamoeba 
keratitis
The success of oral miltefosine suggests that it can 
be absorbed easily by the gut, is able to survive the first 
pass effect in the liver and the bioavailability in the eye 
is of sufficient concentration to cause Acanthamoeba 
death. This suggests that lower doses would be sufficient 
for topical use. Work done by Polat et al.33 demonstrated 
that the topical application of miltefosine alone to the 
Acathamoeba-infected eyes of Syrian hamsters for 28 
days at 160μM cleared AK infections by 85%33 (Table 2). 
In contrast, the current recommended topical treatment 
combinations of 0.1% propamidine isetionate and 0.02% 
PHMB was less effective in the eyes of Syrian hamsters 
than miltefosine alone33. The same group reported further 
benefits for the use of miltefosine as a combined topical 
treatment against Acanthamoeba keratitis in rats34. 
Miltefosine (160μM) combined with PHMB (0.02%) or 
chlorhexidine (0.02%) but not propamidine isethionate 
(0.1%) showed synergistic activity34 (Table 2). This study 
illustrated that existing topical treatments with PHMB 
can be improved by the addition of topical miltefosine. We 
thus propose that miltefosine should be integrated with 
current treatment regimens for improved prognosis for 
patients.
In vitro activity of APCs against Acanthamoeba 
There are several in vitro studies describing the efficacy 
of APC analogues against Acanthamoeba with most 
showing miltefosine (hexadecylphosphocholine) to have 
optimal activity against Acanthamoeba trophozoites (Table 
3). In a structure activity relationship study undertaken 
by Mooney and colleagues, a series of APCs with different 
alkyl-carbon chain length ranging from 8-18 carbons, 
demonstrated that miltefosine was cytotoxic at 46μM 
and cytostatic below this dosage against trophozoites35. 
Another study showed that 39mM to 78mM of miltefosine 
was toxic to cysts36. Similar results reported elsewhere 
for miltefosine16,17,35,37 have shown that the activity of 
miltefosine against Acanthamoeba is influenced by the life 
form16,17,35,36, the Acanthamoeba species16,37, the strain36, 
and the duration of the drug in contact with the protist36. 
Nevertheless, they have shown that approximately 3000-
fold lower concentrations of miltefosine was required for 
in vitro treatment than for topical and oral application13,32,33 
(Table 3). This makes a good case for their incorporation 
into contact lens solutions as a preventive strategy. Studies 
show that human tissues such as the eye, organotypic skin 
models and mammalian breast cancer cells are refractory 
to miltefosine concentrations 160µM, 50μM and 150mM 
respectively19,33,34,38,39 which suggest that it could be safe to 
use as a preventive strategy and eye toxicity would not be 
an issue.
Quaternary Ammonium Compounds Against 
Acanthamoeba 
Structure and classification of quaternary ammonium 
compounds
QACs lack the negatively charged phosphoryl group 
of APCs resulting in a net positive charge. They are 
cationic molecules containing a positively charged 
central nitrogen atom attached to four substituents. 
Attachments to aliphatic and aromatic functional groups 
have produced two main types of QACs. In this review, 
they will be referred to as benzylated and non-benzylated 
if the compound contains an aromatic benzyl ring (e.g. 
benzalkonium chloride and benzethonium chloride) 
or lacks one (e.g. tetraethylammonium bromide and 
dodecyltrimethylammonium bromide) attached to the 
nitrogen atom respectively (Figure 2). 
Activity of quaternary ammonium compounds 
against Acanthamoeba 
Broad antimicrobial properties against virus, bacteria 
and protozoans have been reported in 1,866 studies since 
201540–42. The activity of both QACs against Acanthamoeba 
has also been reported recently35,43–45. Benzylated QACs 
such as benzalkonium chloride (BAC) have widespread 
clinical applications, commonly used in ophthalmic 
Mooney R, Williams R. Alkylphosphocholines and Quaternary Ammonium Compounds 
against Acanthamoeba Keratitis. J Ophthalmol Sci. 2020;2(2):5-14 Journal of Ophthalmological Science
Page 10 of 14
Table 2: Topical miltefosine against Acanthamoeba keratitis
Experimental 
details Preparation Experimental treatments Key Findings Ref.
AK eye model 
from 40 male 
Syrian ham-
sters divided 
into 3 groups
Miltefosine 
prepared 
at 2mM 
dissolved in 
5% ethanol
Group 1 - Miltefosine 
(160μM) 
Group 2 - Propamidine 
isethionate (0.1%) and 
PHMB (0.02%) combina-
tion
Infected Control group - 
Ethanol (0.05%) in PBS 
Each regime was used to 
treat Acanthamoeba-in-
fected eyes for 28 days
Group 1 – 85% of eyes were normal with cultures of excised post-treatment 
tissues negative for Acanthamoeba 
Group 2 – 65% of eyes were normal with 5% cultures of excised post infec-
tion tissues positive for Acanthamoeba. 
Infected Control group – 5% of eyes were normal with 6% of culture of 
excised tissues positive for Acanthamoeba. 
Conclusion; Topical miltefosine was more effective in treating AK than prop-
amidine isethionate and PHMB combinations often used in treating AK.
33
AK eye model 
from 63 male 
Wistar rats 
divided into 7 
groups.
2mM of 
Miltefosine 
prepared at 
2mM in 5% 
ethanol
Group 1 - Miltefosine 
(160μM) 
Group 2 – chlorhexidine 
gluconate (0.02%) 
Group 3 – PHMB (0.02%) 
Group 4 – propamidine 
isethionate (0.1%) 
Group 5 – Miltefosine 
(160μM) and chlorhex-
idine gluconate (0.02%) 
combination
Group 6 – Miltefosine 
(160μM) and PHMB 
(0.02%) combination
Group 7 – Miltefosine 
(160μM) and propami-
dine isethionate (0.1%) 
combination
Infected Control group - 
Ethanol in PBS (0.05%)
Each regime was used to 
treat Acanthamoeba-in-
fected eyes for 28 days
Group 1 – 14.2% and 50% of eyes were normal or almost normal respective-
ly with 28.5% cultures of excised tissues positive for Acanthamoeba.
Group 2 – 7.1% and 50% of eyes were normal or almost normal respectively 
with 28.5% of cultures of excised tissues positive for Acanthamoeba.
Group 3 – 7.1% and 42.8% of eyes were normal or almost normal respec-
tively with 21.4% cultures of excised tissues positive for Acanthamoeba.
Group 4 – 7.1% and 35.5% of eyes were normal or almost normal with 
28.5% cultures of excised tissue positive for Acanthamoeba.
Group 5 –14.2% and 57.1% of eyes were normal or almost normal respec-
tively with 21.4% cultures of excised tissues positive for Acanthamoeba.
Group 6 – 28.4% and 64.2% of eyes were normal or almost normal respec-
tively with 14.2% cultures of excised tissue positive for Acanthamoeba.
Group 7 – 7.1% and 35.5% of eyes were normal or almost normal respec-
tively with 21.4% of cultures of excised tissues positive for Acanthamoeba.
Infected Control group - 0% and 21.4% of eyes were normal or almost nor-
mal respectively with 71.4% cultures of excised tissues positive for Acan-
thamoeba.
Conclusion; Topical treatments of miltefosine combined with PHMB or chlor-
hexidine were synergistic; while combinations with propamidine isethionate 
were additive. PHMB-miltefosine combination is an effective treatment for 
AK.
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Figure 2: General structures of benzylated QACs. The molecules contain a positively charged nitrogen group attached to (a) two methyl 
groups and a benzyl ring (benzylated) or (b) three methyl groups (non-benzylated). “n” indicates the variable alkyl-carbon tail.
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Class Compound name Experimental conditions Key Findings Ref.
APCs
APC: 
Hexadecyl-PC (Miltefosine), 
Octadeyl-PC, Eicosanyl-PC, 
(Z)-12-heneicosenyl-PC, 
(Z)-13-docosenyl-PC, (Z)-10-
docosenyl-PC, (Z,Z)-6, 12-eico-
sadienyl-PC, (Z,Z)-6,15-tetraco-
sadienyl-PC
 A. castellanii, A. polyphaga, A. lentic-
ulata trophozoites and cysts treated 
with miltefosine at concentration 
ranging from 5-160μM for 72 hours.
Findings: Miltefosine was most effective against 
A. castellanii and A. polyphaga trophozoites (MIC, 
40μM) and A. lenticulata trophozoites 80μM. These 
concentrations killed 60%-80% of cysts of all strains.
Conclusions: Miltefosine had species-specific 
activity against Acanthamoeba at low micromolar 
concentrations in vitro. 
16
APC: Hexadecyl-PC (Miltefosine)
Trophozoites of A. castellanii, A. 
polyphaga (2 strains), Unknown Acan-
thamoeba sp. treated with miltefosine 
at concentrations ranging from 10-
80μM for 1 week
Findings: Miltefosine killed Acanthamoeba spp. at 
concentrations above 40μM with recovery within 
1-2 weeks below this concentration. 
 Conclusion: Miltefosine had concentration-depen-
dent cytostatic and cytotoxic activity. 
17
APC: Hexadecyl-PC (Miltefosine)
Cysts of three environmental isolates 
within T3, T4 and T5 genotypes were 
treated with miltefosine at concentra-
tions ranging from 2.42-77.44mM for 
1 week
Findings: minimal cysticidal concentration for cysts 
of the T4 and T5 genotypes were killed after 1 day 
at 38.72mM while for T3 cysts, it was 77.44mM. At 
7 days it decreased 9.68mM, 4.84mM and 4.84mM 
for the T3, T4 and T5 genotypes respectively.
Conclusion: The species- and life form-specific activ-
ity of miltefosine against Acanthamoeba was time 
dependent. Activity on environmental isolates was 
significantly higher than lab-derived strains. 
36
APC: 
Hexadecyl-PC (Miltefosine), 
octadecyl-PC, elaidyl-PC, eru-
cyl-PC, edelfosine
Trophozoites of A. castellanii, A. 
polyphaga incubated with miltefosine 
at concentrations ranging from 7.8-
1000μM for 96 hours. 
Findings: The order of activity against Acanthamoe-
ba spp. was Hexadecyl-PC > octadecyl-PC albeit 
with A. castellanii more susceptible than A. polyph-
aga. MIC for hexadecyl-PC was 62.5μM and 125μM 
for A. castellanii and A. polyphaga respectively.
Conclusion: Species-specific activity of miltefosine 
against Acanthamoeba was highlighted, vital to 
inform a preventative strategy.
37
QACs
nbQAC: Polyquad-1
Cysts of A. castellanii, A. polyphaga, 
A. hatchetti treated with 0.001% Poly-
quad-1 formulated in the contact lens 
solutions Alcon Opti-Clean II, Alcon 
Opti-Free Express, Alcon Opti-Free 
Replenish for 24 hours
Findings: Viable cysts were observed for all 3 
Acanthamoeba spp. after 24 hours incubation in all 
Polyquad-1 -contact lens solution formulations
Conclusion: Polyquad-1 concentrations in contact 
lens solutions are inactive against Acanthamoeba 
cysts
11
bQAC: Benzalkonium chloride (BAC)
Trophozoites and cysts of A. castel-
lanii, A. polyphaga treated with BAC 
at concentrations ranging from 2.7-
134μM (0.005-0.02%) for 48 hours in 
the BAC containing solutions Levoflox-
acin (Oftaquix; 0.005% BAC), trifluoro-
thymidine ( 0.02% BAC)
Findings: BAC monotherapy was effective in killing 
trophozoites at concentrations of 0.02μM and 
0.005μM and cysts at concentrations of 0.04μM 
and 0.02μM for A.castellanii and A.polyphaga 
respectively. The Levofloxacin (Oftaquix) ophthalmic 
solution with 0.005% BAC has a minimal amoebi-
cidal concentration of 156μg/ml and 312μg/ml and 
cysticidal concentration of 625μg/ml and 625μg/ml 
for A.castellanii and A. polyphaga respectively. For 
TMT containing 0.02% BAC these same respective 
concentrations were 625μg/ml and 1250μg/ml for 
trophozoites and 5000μg/ml and 2500μg/ml for 
cysts. 
Conclusion: BAC is highly potent to Acanthamoeba 
trophozoites and cysts and addition to contact lens 
solutions significantly increases efficacy.
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Table 3: In vitro APCs and QACs against Acanthamoeba
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bQAC: 
nbQAC: 
Benzalkonium chloride (BAC) 
Polyquad-1
Trophozoites and cysts of A. castellanii 
(2 strains), A. polyphaga (2 strains), A. 
mauritaniensis (6 strains) at concen-
trations ranging from 2.7-134μM 
(0.005-0.02%) for up to 8 hours in the 
QAC containing solutions, Duracare 
(0.004% BAC), Optifree (0.001% 
Polyquad-1), Optisoak (0.05% Poly-
quad-1), Oxysept 1 Step (0.004% BAC), 
Transoak (0.01% BAC), Transol Wetting 
Solution (0.004% BAC)
Findings: 0.01% BAC in Transoak was most effective 
and killed cysts from all species and strains within 
four hours. Lower BAC concentrations present in 
Duracare (0.004%) and Transol (0.004%) required 
more than 8 hours to produce similar activity 
against cysts. Optifree and Optisoak containing 
Polyquad-1 had no cysticidal activity for all Acan-
thamoeba species and strain. 
Conclusion: Benzylated QACs as a medical device 
demonstrated better activity against Acanthamoeba 
trophozoites and cysts than their non-benzylated 
counterpart.
43
APC and QAC
nbQAC: 
APC: 
Dodecyl-TMAB, Tetrade-
cyl-TMAB, Hexadecyl-TMAB, 
Octadecyl-TMAB 
Dodecyl-PC, Tetradecyl-PC, 
Hexadecyl-PC (Miltefosine)
Trophozoites and cysts of A. castellanii 
at concentrations ranging from 0.5-
400μM for 96 hours.
Findings: Octadecyl-TMAB and miltefosine (hexade-
cyl-PC) were most effective QAC and APCs against 
Acanthamoeba trophozoites respectively, with the 
nbQACs, Octadecyl-TMAB cytotoxic at low con-
centrations and demonstrated cysticidal activity 
after 24 hours. Dodecyl-TMAB and miltefosine was 
synergistic. 
Conclusion: nbQACs more effective than APCs and 
demonstrated higher cysticidal activity but synergis-
tic when combined. 
35
nbQAC: 
bQAC: 
APC: 
Cetyl-TMAB 
Cetylpyridinium bromide,Ben-
zethonium chloride (BAC)
Hexadecyl-PC (Miltefosine), 
Erucylphosphohomocholine, 
Perifosine, N-benzyl-N,N-di-
methyl-N-hexadecyl-AB
Trophozoites of A. lugdunensis, A. 
quina at concentrations ranging from 
0.98-500μM for 48 hours
Findings: The QACs cetyl-TMAB, cetylpyridinium 
bromide and N-benzyl-N,N-dimethyl-N-hexadec-
ylammonium bromide were most effective against 
both Acanthamoeba spp with comparable MICs, 
15.6μM. 
Conclusion: QACs are more effective against Acan-
thamoeba trophozoites than APCs.
45
Key: bQAC – benzylated QAC, nbQAC – non-benzylated QAC, -TMAB – trimethyl ammonium bromide, -PC - Phosphocholine
solutions as topical and preventive strategies, and can cause 
death at concentrations ranging from 2.69μM to 20.97M 
and 20.97μM to 41.93μM against trophozoites and cysts 
respectively46, far lower than that in ophthalmic solutions 
being 107.52μM43. Lower concentrations of benzylated 
QACs formulated in medical devices with longer incubation 
times in cytotoxicity assays have increased efficacy31,43. 
To date, the activity of benzylated QACs against different 
Acanthamoeba species, strains and their respective life 
forms have been reported8,41-43. The unusually structured 
non-benzylated-QAC, Polyquaternium-1, widely used in 
ophthalmic solutions, has no cysticidal activity against 
Acanthamoeba11,47. However, other non-benzylated 
compounds have reported alkyl carbon length dependent 
efficacy against trophozoites and cysts35. The non-
benzylated QAC, dodecyltrimethylammonium bromide 
(DTAB) with 12 alkyl-carbon atoms was non-toxic against 
Acanthamoeba trophozoites or cysts at concentrations up 
to 486μM35. Interestingly, their benzylated counterpart 
was active at 1.6mM35,48. The 18-carbon analogue, 
octadecyltrimethylammonium bromide (OTAB) was the 
most toxic (IC50; trophozoites; 17.6μM and cyst; 38.2μM)35. 
This structural variation is linked to the ability of the 
compounds to produce death by micelle formation35. In 
vitro structure-activity relationship analysis have revealed 
that the net charge is another major determinant of 
the activity of this compound against trophozoites; 
cationic>zwitterionic>anionic35,49. Cationic molecules 
can rapidly reverse the net negative charge of the plasma 
membrane to produce shock due to the opposing charge 
of the molecule50. It has been shown that toxicity to 
human cells can be an issue, but currently available 
data only investigates higher concentrations than those 
recorded as toxic against Acanthamoeba. For example, 
octadecyltrimethylammonium bromide causes severe 
eye irritation at concentrations above 510mM, while 
~1200-fold (42µM) lower doses are required for activity 
against Acanthamoeba. Nevertheless, studies are required 
to validate QACs as a preventative strategy35,51. Should 
corneal toxicity be an issue, neutralising agents such as 
β-cyclodextrin could provide a second step during contact 
lens cleansing52. Two-step methods have been effectively 
used for hydrogen peroxide based contact lens solutions13.
Conclusion
The impact of APCs in AK treatments, even amongst 
the ‘difficult to treat’ immuno-suppressed patients is 
promising15,28,32. Despite the clinically observed effect, little 
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is known about its clinical pharmacodynamics, mainly 
because good quantitative markers of parasite load and 
treatment response are not available for AK. Disease-
specific pharmacokinetics for miltefosine alone53 and 
in combination54 are available for other anti-parasitic 
infections e.g. Leishmaniasis but are yet to be available 
for AK. Further clinical research is required for these 
compounds use against AK. The studies highlighted in 
this review suggest that miltefosine may reduce current 
prolonged treatment regime and prevent cyst-induced 
disease resurgence, common with current curative and 
preventive treatments. Similarly, pharmacodynamics and 
pharmacokinetic for QACs are scarce and are perhaps 
hampered by their extensive use as preservatives. The 
strong efficacy of QACs against Acanthamoeba is a 
framework for development as a treatment or preventative 
for AK, if corneal toxicity issues are addressed.
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